Advertisement

Topics

Search Results for "Ondansetron Im"

06:58 EDT 28th July 2017 | BioPortfolio

Matching Channels

None

Matching News

Global and Chinese Ondansetron hcl Industry, 2017 Market Research Report [Report Updated: 21062017] Prices from USD $3000

The 'Global and Chinese Ondansetron hcl Industry, 20122022 Market Research Report' is a professional and indepth study on the current state of the global Ondansetron hcl industry with a focus on the C...

Global and Chinese Ondansetron base Industry, 2017 Market Research Report [Report Updated: 21062017] Prices from USD $3000

The 'Global and Chinese Ondansetron base Industry, 20122022 Market Research Report' is a professional and indepth study on the current state of the global Ondansetron base industry with a focus on the...

Tackling Acute Gastroenteritis: RedHill Biopharma's Bekinda A Novel Approach?

A new long-acting ondansetron product that reduces nausea and vomiting during acute viral gastroenteritis, whatever the type of virus involved...   

RedHill Biopharma Receives Notice of Allowance for Two Additional U.S. Patents Covering BEKINDA®

RedHill received Notices of Allowance from the United States Patent and Trademark Office (USPTO) for two new patents covering BEKINDA® (RHB-102), expected to be valid until at least 2034, once gran...

Cimab SA Pharmaceuticals Healthcare Deals and Alliances Profile [Updated: 10032017] Prices from USD $250

SummaryCimab SA Cimab is a biopharmaceutical company that develops and markets monoclonal antibodies and other recombinant proteins for the diagnosis and treatment of cancer and other diseases related...

Cimab SA Pharmaceuticals Healthcare Deals and Alliances Profile [Updated: 23022017] Prices from USD $250

SummaryCimab SA Cimab is a biopharmaceutical company that develops and markets monoclonal antibodies and other recombinant proteins for the diagnosis and treatment of cancer and other diseases related...

RedHill Biopharma Announces Enrollment of Last Patient in the BEKINDA® Phase II Study for IBS-D

Top-line results are expected in the third quarter of 2017  The randomized, double-blind, placebo-controlled Phase II study is evaluating the safety and efficacy of BEKINDA® (RHB-102) 12 mg in...

RedHill Biopharma Announces Last Patient Visit in BEKINDA® Phase II Study for IBS-D

Top-line results are expected in September 2017  The randomized, double-blind, placebo-controlled Phase II study is evaluating the safety and efficacy of BEKINDA® (RHB-102) 12 mg in 127 U.S. p...

Matching PubMed Articles

A randomised controlled trial of placebo, droperidol or ondansetron to prevent nausea and vomiting after tonsillectomy in children receiving dexamethasone.

We tested whether prophylactic droperidol and ondansetron, in combination with a moderate dose of dexamethasone, were equally effective in reducing nausea and vomiting after tonsillectomy in children ...

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron.

5-hydroxytryptamine type 3 (5-HT3 ) receptor antagonists are used in the prevention of chemotherapy- induced, radiation-induced and postoperative nausea and vomiting. CYP2D6 polymorphisms can influenc...

Addition of droperidol to prophylactic ondansetron and dexamethasone in children at high risk for postoperative vomiting. A randomized, controlled, double-blind study.

: The combination of dexamethasone (DEX), ondansetron (OND) and droperidol (DRO) is efficacious in preventing postoperative nausea and vomiting in adults, but has not been well assessed in children.

Ondansetron Does Not Reduce Withdrawal in Patients With Physical Dependence on Chronic Opioid Therapy.

Individuals taking opioids for an extended period of time may become physically dependent, and will therefore experience opioid withdrawal should they stop taking the medication. Previous work in anim...

Observational Case Series Evaluation of the Granisetron Transdermal Patch System (Sancuso) for the Management of Nausea/Vomiting of Pregnancy.

Objective The objective of this study was to observe the efficacy of antiemetic therapy (no emesis/retching episodes and no rescue medication use) when granisetron is administered via a transdermal ...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement